Search

Company's CEO and CFO Highlights its Cutting-Edge Gene Therapy Programs AUSTIN, Texas, Sept. 23, 2024 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4260023-1&h=1442830600&u=https%3A%2F%2Fwww.genprex.com%2F&a=Genprex%2C+Inc.('Genprex' or the 'Company') (NASDAQ: GNPX), a clinical-stage gene therapy company focused on [...]

CUPERTINO, Calif., Sept. 10, 2024 /PRNewswire/ --Oneness Biotech and Microbio (Shanghai) announced that the pan-COVID New Drug, SNS812, co-developed by both companies achieves statistical significance with clinically meaningful endpoints in [...]

First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18, 2024 /PRNewswire/ -- Boehringer Ingelheim and GoodRx (Nasdaq: GDRX), the [...]

Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit Funding for the study comes from the US$5 million Therapeutic [...]

TREMFYA Phase 3 Crohn's disease study achieves all primary and secondary endpoints SPRING HOUSE, Pa., June 20, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results [...]

SUZHOU, China, and ROCKVILLE, Md., June 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related [...]

Frank Nestle, MD, FMedSci joins Deerfield from previous position as Global Head of Research and Chief Scientific Officer at Sanofi Nestle will lead therapeutic discovery and development as Partner and [...]

CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR [...]

Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE(TM)) platform BHV-1300 demonstrates dose-dependent and [...]

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 15, 2024 /PRNewswire/ -- https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ -- Hope is rising in the fight against one of the [...]

BASEL, Switzerland, May 6, 2024 /PRNewswire/ -- Allegria Therapeutics ('ALLEGRIA'), a Swiss biotech company redefining the treatment landscape of therapeutics for mast cell-mediated diseases, announced today a Seed Financing of [...]

JERSEY CITY, N.J., May 3, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of an abstract in amyotrophic lateral sclerosis (ALS) at the Professional Society [...]

FDA ODAC unanimously votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTIbased on results from the Phase 3 CARTITUDE-4 study RARITAN, N.J., March 15, 2024 /PRNewswire/ -- Johnson & [...]

Designation follows December 2023 FDA approval for the treatment of these serious, potentially life-threatening fungal infections in children CRESEMBA receives seven years and six months of US market exclusivity for [...]

-- Retrospective analysis suggests Acthar Gel treatment was associated with similar improvement in health status and overall symptom reduction in African Americans and non-African Americans with symptomatic sarcoidosis[sup.1] -- -- [...]

RAHWAY, N.J., Feb. 7, 2024 /PRNewswire/ -- Multiple sclerosis (MS) may be a common disorder, but the journey to diagnosis and understanding of the illness may still lead to confusion [...]

SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib­êABSK021­ë has been granted orphan drug [...]

DUBLIN, Dec. 6, 2023 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5868001/cardiac-bio-implant-devices-market-size-global?utm_source=CI&utm_medium=PressRelease&utm_code=tf22wb&utm_campaign=1916691+-+Cardiac+Bio+Implant+Devices+Market+Report+2023-2030%2c+Featuring+F.+Hoffman-La+Roche%2c+Eurofins+Scientific%2c+Illumina%2c+Natera%2c+Abbott+Laboratories+and+Agilent+Technologies&utm_exec=cari18prd report has been added toResearchAndMarkets.com's offering. The Global Cardiac Bio-Implants Device Market size is estimated to be US$ 60.20 Billion by 2030. [...]

This submission is supported by data from the Phase 3 MARIPOSA-2 Study featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress and simultaneously published in Annals of [...]

LANSING, Mich., Nov. 15, 2023 /PRNewswire/ -- Ionetix Corporation today announced the signing of a supply agreement for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer. Under the terms of the [...]

Three women diagnosed with HER2- HR+ advanced breast cancer in Mozambique have begun treatment, with efforts underway to open access in eight additional countries The Max Foundation leading initiative through [...]

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related [...]

Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates CAMBRIDGE, Mass., Nov. 2, 2023 /PRNewswire/ -- Bayer and the Broad Institute of MIT and Harvard have renewed their [...]

PITTSBURGH, Oct. 30, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4009454-1&h=2637115249&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc.(NASDAQ: VTRS), a global healthcare company, announced today it is hosting https://c212.net/c/link/?t=0&l=en&o=4009454-1&h=455235475&u=https%3A%2F%2Fnasdaq.zoom.us%2Fwebinar%2Fregister%2FWN_WFIeSKldQeu0PGhSMK7LfQ%23%2Fregistration&a=The+Power+of+Partnership+to+Address+Antimicrobial+Resistance+(AMR), a Nasdaq webinar that will air on Tuesday, November 14, 2023 at [...]

NASHVILLE, Tenn., Oct. 10, 2023 /PRNewswire/ --Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy [sup.1] detailing the results of the first clinical study [...]

Doctor shares what patients and parents need to know about antibiotics, cotton swabs and ear candling RAHWAY, N.J., Oct. 3, 2023 /PRNewswire/ -- Most of us can remember the intense [...]

PLYMOUTH, Mich., Oct. 3, 2023 /PRNewswire/ -- Esperovax, a U.S.-based preclinical biopharmaceutical company and a BLUE KNIGHT(TM) resident company, is receiving an award for $ 1 M to further develop [...]

Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies BOSTON and SAN DIEGO and CALGARY, AB, Sept. 26, 2023 /PRNewswire/ -- [...]

Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies BOSTON, SAN DIEGO, and CALGARY, AB, Sept. 26, 2023 /PRNewswire/ -- In [...]

Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive diseaseà; more than 147,000 breast cancer patients in Europe die [...]

Lung cancer is a type of cancer that begins in the lungs. It is one of the leading causes of cancer-related deaths worldwide. Lung cancer is often categorized into two [...]

The collaboration aims to identify disease-modifying interventions, with the goal of improving standards of care for people living with type 2 diabetes and cardiac fibrosis CAMBRIDGE, Mass., Sept. 6, 2023 [...]

Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive diseaseà; more than 147,000 breast cancer patients in Europe die [...]

-- Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption -- [...]

DUBLIN, April 27, 2023 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5780713/global-antibiotics-market-distribution-type?utm_source=CI&utm_medium=PressRelease&utm_code=wf47qz&utm_campaign=1844994+-+Global+Antibiotics+Market+Report+2023%3a+Featuring+Bayer%2c+Fujisawa+Pharmaceutical%2c+GlaxoSmithKline%2c+Merck+and+More&utm_exec=como322prd report has been added toResearchAndMarkets.com's offering. The report features an extensive study of the current market landscape and future opportunity for the [...]

NEW YORK, April 26, 2023 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today [...]

Leadership committee seeks to bring resolution to decade-long legal battle ST. LOUIS, April 21, 2023 /PRNewswire/ -- Lawyers representing approximately 55,000 plaintiffs in the litigation against Johnson & Johnson (NYSE: [...]

LEUVEN, Belgium, STRASBOURG, France, and PHILADELPHIA, April 4, 2023 /PRNewswire/ -- Flamingo Therapeutics ('Flamingo') today announced the appointment of Andrew E. Denker, MD, PhD., as Chief Medical Officer. Dr. Denker [...]

The collaboration aims to advance health equity and improve health outcomes for people at risk for breast and cervical cancers in underserved communities by creating a scalable model for prevention [...]

DUBLIN, Feb. 9, 2023 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5733610/therapeutic-contact-lenses-market-global?utm_source=CI&utm_medium=PressRelease&utm_code=5d7pq7&utm_campaign=1817950+-+Insights+on+the+Therapeutic+Contact+Lenses+Global+Market+to+2027+-+Increase+in+Silicone+Hydrogel+Contact+Lenses+Application+Presents+Opportunities&utm_exec=jamu273prd report has been added toResearchAndMarkets.com's offering. The global therapeutic contact lenses market is expected to grow at a CAGR of 4.90% from [...]

Tetra and Cellvera to jointly develop an orally administered treatment, ARDS-003, in combination with the proven broad-spectrum antiviral, Qifenda 400MG (Favipiravir) Companies will jointly develop a combination therapeutic candidate for [...]

New, classic fall flavor joins brand's best-selling lineup of CBD products SMITHS FALLS, ON and NEW YORK, Aug. 15, 2022 /PRNewswire/ - Today, Martha Stewart CBD unveiled the latest flavor [...]

As the first and only biologic targeting both cytokines interleukin (IL)-12 and IL-23, STELARA provides a new therapeutic option for children six years of age and older living with active [...]

New research published in The New England Journal of Medicine reveals that people with certain genetic loss-of-function mutations have more than 50% lower risk of nonalcoholic liver disease and nonalcoholic [...]

Rona to advance worldwide development of Sanofi siRNA portfolio targeting liver and other tissues Rona licensed Sanofi's siRNA platform to enable discovery programs in expanded therapeutic areas including neuro and [...]

DUBLIN, July 5, 2022 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5615434/global-hospital-acquired-infection-diagnostics?utm_source=CI&utm_medium=PressRelease&utm_code=xtqhsz&utm_campaign=1720733+-+Global+Hospital-Acquired+Infection+Diagnostics+Market+Report+2022%3a+Featuring+Key+Players+Bayer%2c+Danaher%2c+Pfizer+%26+Others&utm_exec=como322prd report has been added toResearchAndMarkets.com's offering. The Global Hospital-Acquired Infection Diagnostics Market size is expected to reach $5.6 billion by 2028, rising [...]

Lausanne-based +ND Capital's investment strategy delivers again as Galapagos acquires CellPoint for[euro]125m cash upfront and up to[euro]100m in milestone payments Potential for paradigm shift in CAR-T therapy with CellPoint's decentralized [...]

NEW BRUNSWICK, N.J., June 8, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today published its https://c212.net/c/link/?t=0&l=en&o=3560693-1&h=1880981945&u=https%3A%2F%2Fhealthforhumanityreport.jnj.com%2F&a=2021+Health+for+Humanity+Report, which shares progress against its purpose-driven https://c212.net/c/link/?t=0&l=en&o=3560693-1&h=687932277&u=https%3A%2F%2Fwww.jnj.com%2Fhealth-for-humanity-goals-2025&a=Health+for+Humanity+2025+Goals and serves as its annual disclosure [...]

Consortium of Hackensack Meridian CDI, Rockefeller University, Columbia University, Memorial Sloan Kettering Cancer Center, Rutgers University, Merck, Tri-Institutional Therapeutics Discovery Institute, Inc., and Aligos Therapeutics to combine expertise to 'accelerate' [...]

Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisai's Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for Patients Presentations Featuring Post-Hoc Analyses from the [...]